AngioDynamics
ANGO
14.19
-0.23
-1.60%
AngioDynamics
US · ANGO
#3631 by market cap
14.19
-0.23
-1.60%
Live - 5344 symbols - heartbeat 222s ago
· 2026-10-08 09:19
Pre-market
13.74
-3.20%
After-hours
14.61
+2.96%
Overnight
14.50
+2.18%
- Market cap
- 596.75M
- P/E (TTM)i
- -16.13
- P/Bi
- 3.49
- EPSi
- -0.88
- Div yieldi
- 0.00%
- 52W posi
- 70%
Reader sentiment
Are you bullish or bearish on ANGO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 2 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.3 percentage points.
Institutional ownership
- Held by institutions
- 93.43% +0.34pp
- Institutions
- 197 -2
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund57.36%
Hedge Fund32.09%
Individual/Insider10.36%
Public Company2.11%
Insurance Company1.13%
Government Pension Fund0.43%
Private Company0.17%
Family Office/Trust0.13%
Top holders as of 2026-06-30
BlackRock
9.20% · 3.80M sh
Point72 Asset Management, L.P.
7.41% · 3.06M sh
Systematic Financial Management LP
6.39% · 2.64M sh
Kevin Kotler
5.86% · 2.42M sh
Armistice Capital LLC
5.32% · 2.20M sh
Vanguard Capital Management, LLC
4.77% · 1.97M sh
Royce & Associates, LP
4.77% · 1.97M sh
Broadfin Capital, LLC
4.40% · 1.82M sh
Weber Capital Management, LLC
3.28% · 1.36M sh
Teachers Insurance and Annuity Association-College Retirement Equities Fund
2.65% · 1.10M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| James Clemmer | Chief Executive Officer | 1.52% |
| Howard Donnelly | Independent Non-Executive Chairperson | 0.43% |
| Stephen Trowbridge | Chief Financial Officer | 0.39% |
| Wesley Johnson | Independent Director | 0.38% |
| Jan Reed | Independent Director | 0.28% |
| Eileen Auen | Independent Director | 0.28% |
| Karen Licitra | Independent Director | 0.25% |
| Michael Tarnoff | Independent Director | 0.23% |
| Laura Piccinini | Senior VP & GM of International | 0.20% |
| Lorinda Burgess | Independent Director | 0.16% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-07-29 | Warren Nighan | Senior Vice President of Quality & Regulatory Affairs | Open Market Disposition | -23,370 | $14.72 |
| 2026-07-21 | Warren Nighan | Senior Vice President of Quality & Regulatory Affairs | Derivative Exercise and Sale | -1,671 | $13.82 |
| 2026-07-21 | Warren Nighan | Senior Vice President of Quality & Regulatory Affairs | Derivative Exercise and Retained | +4,023 | -- |
| 2026-07-21 | James Clemmer | Chief Executive Officer | Derivative Exercise and Sale | -26,728 | $13.82 |
| 2026-07-21 | James Clemmer | Chief Executive Officer | Derivative Exercise and Retained | +25,630 | -- |
| 2026-07-21 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Sale | -8,319 | $13.82 |
| 2026-07-21 | Stephen Trowbridge | Chief Financial Officer | Derivative Exercise and Retained | +7,977 | -- |
| 2026-07-21 | Laura Piccinini | Senior VP & GM of International | Derivative Exercise and Sale | -4,506 | $13.82 |
| 2026-07-21 | Laura Piccinini | Senior VP & GM of International | Derivative Exercise and Retained | +3,541 | -- |
| 2026-07-21 | Chad Campbell | Senior VP and GM of Vascular Access & Oncology Global Business Unit | Derivative Exercise and Sale | -2,330 | $13.82 |
| 2026-07-21 | Chad Campbell | Senior VP and GM of Vascular Access & Oncology Global Business Unit | Derivative Exercise and Retained | +4,136 | -- |
| 2026-07-19 | Warren Nighan | Senior Vice President of Quality & Regulatory Affairs | Sale to Issuer | -3,777 | $13.51–14.14 |
| 2026-07-19 | James Clemmer | Chief Executive Officer | Sale to Issuer | -45,711 | $13.51–14.14 |
| 2026-07-19 | Stephen Trowbridge | Chief Financial Officer | Sale to Issuer | -12,067 | $13.51–14.14 |
| 2026-07-19 | Laura Piccinini | Senior VP & GM of International | Sale to Issuer | -8,228 | $13.51–14.14 |
| 2026-07-19 | Chad Campbell | Senior VP and GM of Vascular Access & Oncology Global Business Unit | Sale to Issuer | -3,838 | $13.51–14.14 |
| 2026-07-15 | Lawrence Weiss | Chief Legal Officer | Sale to Issuer | -2,267 | $14.14 |
| 2026-07-14 | Jan Reed | Independent Director | Other Acquisition | +11,887 | -- |
| 2026-07-14 | Wesley Johnson | Independent Director | Other Acquisition | +11,887 | -- |
| 2026-07-14 | Howard Donnelly | Independent Non-Executive Chairperson | Other Acquisition | +11,887 | -- |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 09:19:27 · For reference only, not investment advice and not tailored to your situation.